alefacept (Amevive)

01/01/2010 - "Alefacept treatment is highly effective in a select group patients with moderate-to-severe psoriasis, and is an ideal candidate to develop systems to predict who will respond to therapy. "
01/01/2007 - "Alefacept is a very safe treatment for psoriasis alone or in conjunction with other therapies. "
08/01/2003 - "We conclude that alefacept significantly improves psoriasis and produces durable clinical improvement with a very favorable safety profile."
01/01/2003 - "black triangle In placebo-controlled studies, once-weekly administration of alefacept 7.5mg intravenous (IV) and 15mg intramuscular (IM) for 12 weeks significantly improved psoriasis and produced durable clinical improvements in patients with moderate-to-severe chronic plaque psoriasis who responded. "
12/01/2002 - "In previous phase II studies, alefacept significantly improved psoriasis and was well tolerated. "

10/01/2005 - "In addition, data are reviewed on the use of alefacept in combination with other agents and in other diseases, including psoriatic arthritis."
10/01/2004 - "A preliminary study evaluating the use of alefacept for the treatment of active psoriatic arthritis parallels the psoriasis experience and supports the premise of targeting T cells as an intervention for this disease. "
11/01/2005 - "This paper reviews the data supporting the use of alefacept in psoriasis and psoriatic arthritis."
11/01/2005 - "Alefacept for psoriasis and psoriatic arthritis."
10/01/2002 - "Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis."

02/01/2013 - "To evaluate the safety and efficacy of alefacept in the treatment of vitiligo. "
02/01/2013 - "Alefacept as a monotherapy for vitiligo treatment did not result in any patient improvement, and further evaluation in larger studies may be required."
02/01/2013 - "Failure of alefacept in the treatment of vitiligo."
05/01/2009 - "Use of alefacept in vitiligo may turn out to be a possible novel off-label treatment option in vitiligo. "
02/01/2013 - "After providing informed written consent, 4 adult patients with widespread vitiligo (covering a body surface area ≥5%) were treated with weekly intramuscular injections of 15 mg alefacept for 12 weeks. "

01/01/2007 - "Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity."
12/01/2005 - "Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report."
01/01/2009 - "We have shown previously that alefacept is effective in acute steroid resistant/dependent and chronic extensive graft versus host disease (GvHD) with a protocol using timings similar to those used for psoriasis treatment. "
01/01/2009 - "A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus."
06/01/2007 - "Alefacept is potential future therapeutic for organ transplant recipients or graft-vs-host disease and is an approved therapeutic for psoriasis vulgaris, which is a T cell-mediated inflammatory disease. "

11/01/2009 - "To assess the efficacy of alefacept for the treatment of severe alopecia areata (AA). "
11/01/2009 - "Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study."
12/01/2005 - "Alefacept for alopecia areata."
01/01/2007 - "Reported effective off-label uses of alefacept include: generalized lichen planus, alopecia areata, steroid-resistant or steroid-dependent acute graft-versus-host disease, scleroderma, nail psoriasis, and palmoplantar psoriasis."
10/01/2004 - "Research continues to examine the use of alefacept in combination with other systemic psoriasis therapies and phototherapy and its potential as a treatment for other T-cell-mediated diseases, such as psoriatic arthritis, alopecia areata, and rheumatoid arthritis."